SAN DIEGO--(BUSINESS WIRE)--
AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies to treat drug-resistant infections using bacteriophage-based technology, announces that management will hold a business update conference call on Monday, August 14, 2017 beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).
| Live Call: | U.S. | 877-866-5534 | |||
| International | 346-406-0930 | ||||
| Passcode | 53278337 | ||||
| Live Webcast: | |||||
|
The webcast replay will be available approximately 2 hours after completion of the call and will be archived for 30 days. |
|||||
| Replay: | U.S. | 855-859-2056 | |||
| International | 404-537-3406 | ||||
| Passcode | 53278337 | ||||
|
The replay will be available for 48 hours starting approximately 2 hours after completion of the call |
|||||
|
|
|||||
About AmpliPhi Biosciences
AmpliPhi Biosciences Corporation is a biotechnology company pioneering the development and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. In May 2017, AmpliPhi announced a new strategic emphasis on developing precisely targeted and personalized bacteriophage therapies for patients with serious or life-threatening antibiotic-resistant infections. AmpliPhi has reported results from two Phase 1 clinical trials of AB-SA01, one for the treatment of Staphylococcus aureus in chronic rhinosinusitis patients (safety and preliminary efficacy) and one to evaluate the safety of AB-SA01 when administered topically to the intact skin of healthy adults. AmpliPhi has additional bacteriophage-based preclinical products in development, including for the treatment of Pseudomonas aeruginosa infections. AmpliPhi has received positive feedback from the U.S. Food and Drug Administration (FDA) and UK Medicines and Healthcare products Regulatory Agency (MHRA) on its development plans.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170807005009/en/
